Cite
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
MLA
Addison, Christina L., et al. “Correlation of Baseline Biomarkers with Clinical Outcomes and Response to Fulvestrant with Vandetanib or Placebo in Patients with Bone Predominant Metastatic Breast Cancer: An OCOG ZAMBONEY Sub-Study.” Journal of Bone Oncology, vol. 4, no. 2, June 2015, pp. 47–53. EBSCOhost, https://doi.org/10.1016/j.jbo.2015.04.001.
APA
Addison, C. L., Pond, G. R., Cochrane, B., Zhao, H., Chia, S. K., Levine, M. N., & Clemons, M. (2015). Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study. Journal of Bone Oncology, 4(2), 47–53. https://doi.org/10.1016/j.jbo.2015.04.001
Chicago
Addison, Christina L., Gregory R. Pond, Brandy Cochrane, Huijun Zhao, Stephen K. Chia, Mark N. Levine, and Mark Clemons. 2015. “Correlation of Baseline Biomarkers with Clinical Outcomes and Response to Fulvestrant with Vandetanib or Placebo in Patients with Bone Predominant Metastatic Breast Cancer: An OCOG ZAMBONEY Sub-Study.” Journal of Bone Oncology 4 (2): 47–53. doi:10.1016/j.jbo.2015.04.001.